Relmada Therapeutics (RLMD) Corporate presentation summary

Investment highlights and pipeline

• NDV-01, a sustained-release gemcitabine/docetaxel therapy, leads a pipeline targeting non-muscle invasive bladder cancer (NMIBC) with a well-defined regulatory path and strong commercial potential.

• NDV-01 offers improved administration speed, extended tumor exposure, and physician familiarity compared to conventional therapies.

• The pipeline includes multiple late-stage studies for NDV-01 in various NMIBC risk groups and Sepranolone for Prader-Willi syndrome.

• Leadership team has deep expertise in urology and clinical development.

Market opportunity and disease landscape

• NMIBC represents 80% of new bladder cancer cases, with high recurrence rates and a $6.5B annual U.S. treatment cost.

• Recurrence and progression risks are significant, especially for intermediate- and high-risk patients.

• Current treatments involve complex pathways, frequent invasive procedures, and substantial patient burden.

NDV-01 product profile and advantages

• NDV-01 is a ready-to-use, office-based therapy administered in under 5 minutes, enabling broader community adoption.

• Provides sustained intravesical drug release for up to 10 days, enhancing tumor exposure and reducing administration frequency.

• Biodegradable polymer ensures safe excretion, avoiding device extraction required by some competitors.

• Demonstrates stable, predictable drug levels in vitro, minimizing systemic side effects.